This episode contrasts traditional antidepressant treatments with emerging micro-dosing approaches for depression management. Through detailed patient case studies, Host A explores how individuals are supplementing or replacing SSRIs with micro-dosing protocols, while Host B examines the latest clinical trial data on sub-perceptual psilocybin doses. The hosts debate the ethics of self-treatment, analyzing documented risks of drug interactions and the challenges of measuring long-term efficacy in uncontrolled settings. Special attention is given to the role of expectancy effects and the difficulties of conducting double-blind studies with psychedelics.